Share-based Payment Arrangement, Expense of Viracta Therapeutics, Inc. from 31 Dec 2010 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Viracta Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2024.
  • Viracta Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2024 was $1,251,000, a 30% decline year-over-year.
  • Viracta Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2024 was $6,248,000, a 22% decline year-over-year.
  • Viracta Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,649,000, a 44% decline from 2022.
  • Viracta Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $13,548,000, a 144% increase from 2021.
  • Viracta Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $5,542,000, a 1493% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Viracta Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $6,248,000 $1,251,000 -$525,000 -30% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $6,773,000 $1,376,000 -$601,000 -30% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 $7,374,000 $1,837,000 -$275,000 -13% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $7,649,000 $1,784,000 -$390,000 -18% 01 Oct 2023 31 Dec 2023 10-K 07 Mar 2024 2023 FY
Q3 2023 $8,039,000 $1,776,000 -$5,870,000 -77% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $13,909,000 $1,977,000 +$21,000 +1.1% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $13,888,000 $2,112,000 +$340,000 +19% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $13,548,000 $2,174,000 +$366,000 +20% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q3 2022 $13,182,000 $7,646,000 +$5,942,000 +349% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $7,240,000 $1,956,000 +$570,000 +41% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $6,670,000 $1,772,000 +$1,128,000 +175% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $5,542,000 $1,808,000 +$1,714,000 +1823% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
Q3 2021 $3,828,000 $1,704,000 +$1,604,000 +1604% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $2,224,000 $1,386,000 +$1,318,000 +1938% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $906,000 $644,000 +$558,000 +649% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $348,000 $94,000 +$742,389 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q3 2020 $394,389 $100,000 -$365,000 -78% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $29,389 $68,000 -$326,000 -83% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $296,611 $86,000 -$331,000 -79% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $627,611 $648,389 -$1,100,389 -243% 01 Oct 2019 31 Dec 2019 8-K/A 23 Mar 2021
Q3 2019 $1,728,000 $465,000 -$172,000 -27% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3
Q2 2019 $1,900,000 $394,000 -$258,000 -40% 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $2,158,000 $417,000 -$479,000 -53% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $2,637,000 $452,000 -$157,000 -26% 01 Oct 2018 31 Dec 2018 10-K 10 Mar 2020 2019 FY
Q3 2018 $2,794,000 $637,000 +$136,000 +27% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $2,658,000 $652,000 -$384,000 -37% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $3,042,000 $896,000 +$9,000 +1% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $3,033,000 $609,000 -$432,000 -41% 01 Oct 2017 31 Dec 2017 10-K 07 Mar 2019 2018 FY
Q3 2017 $3,465,000 $501,000 -$590,000 -54% 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018 2018 Q3
Q2 2017 $4,055,000 $1,036,000 -$170,000 -14% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $4,225,000 $887,000 -$566,000 -39% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $4,791,000 $1,041,000 -$668,000 -39% 01 Oct 2016 31 Dec 2016 10-K 09 Mar 2018 2017 FY
Q3 2016 $5,459,000 $1,091,000 -$212,000 -16% 01 Jul 2016 30 Sep 2016 10-Q 02 Nov 2017 2017 Q3
Q2 2016 $5,671,000 $1,206,000 -$162,000 -12% 01 Apr 2016 30 Jun 2016 10-Q 27 Jul 2017 2017 Q2
Q1 2016 $5,833,000 $1,453,000 -$511,000 -26% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017 2017 Q1
Q4 2015 $6,344,000 $1,709,000 -$105,000 -5.8% 01 Oct 2015 31 Dec 2015 10-K 09 Mar 2018 2017 FY
Q3 2015 $6,449,000 $1,303,000 -$332,000 -20% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 $6,781,000 $1,368,000 -$96,000 -6.6% 01 Apr 2015 30 Jun 2015 10-Q 29 Jul 2016 2016 Q2
Q1 2015 $6,877,000 $1,964,000 +$658,000 +50% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q4 2014 $6,219,000 $1,814,000 +$826,000 +84% 01 Oct 2014 31 Dec 2014 10-K 09 Mar 2017 2016 FY
Q3 2014 $5,393,000 $1,635,000 +$602,000 +58% 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015 2015 Q3
Q2 2014 $4,791,000 $1,464,000 +$351,000 +32% 31 Mar 2014 30 Jun 2014 10-Q 30 Jul 2015 2015 Q2
Q1 2014 $4,440,000 $1,306,000 +$555,000 +74% 01 Jan 2014 31 Mar 2014 10-Q 05 May 2015 2015 Q1
Q4 2013 $3,885,000 $988,000 +$283,000 +40% 01 Oct 2013 31 Dec 2013 10-K 14 Mar 2016 2015 FY
Q3 2013 $3,602,000 $1,033,000 +$159,000 +18% 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014 2014 Q3
Q2 2013 $3,443,000 $1,113,000 +$536,000 +93% 01 Apr 2013 30 Jun 2013 10-Q 05 Aug 2014 2014 Q2
Q1 2013 $2,907,000 $751,000 +$183,000 +32% 01 Jan 2013 31 Mar 2013 10-Q 07 May 2014 2014 Q1
Q4 2012 $2,724,000 $705,000 01 Oct 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
Q3 2012 $874,000 +$345,000 +65% 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013 2013 Q3
Q2 2012 $577,000 +$442,000 +327% 01 Apr 2012 30 Jun 2012 10-Q 02 Aug 2013 2013 Q2
Q1 2012 $568,000 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013 2013 Q1
Q3 2011 $529,000 01 Jul 2011 30 Sep 2011 10-Q 08 Nov 2012 2012 Q3
Q2 2011 $135,000 01 Apr 2011 30 Jun 2011 10-Q 09 Aug 2012 2012 Q2

Viracta Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $7,649,000 -$5,899,000 -44% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2024 2023 FY
2022 $13,548,000 +$8,006,000 +144% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 $5,542,000 +$5,194,000 +1493% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
2020 $348,000 -$279,611 -45% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
2019 $627,611 -$2,009,389 -76% 01 Jan 2019 31 Dec 2019 8-K/A 23 Mar 2021
2018 $2,637,000 -$396,000 -13% 01 Jan 2018 31 Dec 2018 10-K 10 Mar 2020 2019 FY
2017 $3,033,000 -$1,758,000 -37% 01 Jan 2017 31 Dec 2017 10-K 07 Mar 2019 2018 FY
2016 $4,791,000 -$1,553,000 -24% 01 Jan 2016 31 Dec 2016 10-K 09 Mar 2018 2017 FY
2015 $6,344,000 +$125,000 +2% 01 Jan 2015 31 Dec 2015 10-K 09 Mar 2018 2017 FY
2014 $6,219,000 +$2,334,000 +60% 01 Jan 2014 31 Dec 2014 10-K 09 Mar 2017 2016 FY
2013 $3,885,000 +$1,161,000 +43% 01 Jan 2013 31 Dec 2013 10-K 14 Mar 2016 2015 FY
2012 $2,724,000 +$1,336,000 +96% 01 Jan 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
2011 $1,388,000 +$511,000 +58% 01 Jan 2011 31 Dec 2011 10-K 06 Mar 2014 2013 FY
2010 $877,000 01 Jan 2010 31 Dec 2010 10-K 13 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.